ReviewDiscovery medicine2014
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Review in Discovery medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Prostate cancer research: tools, cell types, and molecular targets.Frontiers in oncology · 2024Review
- The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.International immunopharmacology · 2021Review
- Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.Vaccines · 2021Article
- Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure.Cancer cell international · 2021Article
- Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.Engineering in life sciences · 2021Article
- Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.Biomaterials · 2020Article
- Review
- Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy.Immune network · 2019Review
- Review
- Current and Emerging Targets in Immunotherapy for Osteosarcoma.Journal of oncology · 2019Review
- Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.Archivum immunologiae et therapiae experimentalis · 2018Review
- Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.Cancers · 2018Article
- Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.Journal of hematology & oncology · 2018Article
- Review
- CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Oncotarget · 2017Review
- Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Translational research : the journal of laboratory and clinical medicine · 2017Review
- A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Journal of hematology & oncology · 2017Review
- Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.Cell · 2016Article
- The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy.
Indexed as
Identifiers
25425467PMC12321268W2263192387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.